- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- Analysis
- Focus Articles
- Related Articles1 new
- Instablogs
- StockTalks
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
GILD Market Currents
more »
-
May 11 Gilead (GILD) +3.2% after an FDA advisory panel yesterday backed the company's HIV drug Truvada for use as a preventative measure in high-risk individuals, saying the risk of misuse or the of the virus developing resistance to the treatment didn’t outweigh the potential benefit. The FDA is expected to decide by June 15%. (previous)
Comment![Healthcare, On the Move]
GILD in Focus
more »
GILD Related Articles
more »
GILD News
more »
-
at MarketWatch.com (Fri, 5:25PM)
-
at CNBC.com (May 11, 2012)
-
at MarketWatch.com (Apr 26, 2012)
-
at CNBC.com (Apr 26, 2012)
-
at MarketWatch.com (Apr 26, 2012)
GILD Press Releases and Filings
more »
-
Business Wire (Wed, 4:05PM)
-
Business Wire (May 11, 2012)
-
FDA Advisory Committee Supports Approval of Gilead’s Truvada® for Reducing the Risk of Acquiring HIVBusiness Wire (May 10, 2012)
-
Business Wire (May 8, 2012)
-
Business Wire (May 1, 2012)
GILD Latest Transcript
more »
-
Thu, Apr 26
GILD Cramer
more »
-
Wed, Nov 30, 2011
-
Wed, May 4, 2011
-
Sun, Mar 27, 2011
GILD Instablog posts
more »
GILD vs. ETF Alternatives
Company Description
Gilead Sciences, Inc. (Gilead, we, us or our), incorporated in Delaware on June 22, 1987, is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Our mission is to advance the care of patients suffering from life... More
